99 LC-MS/MS-method validation quantifying emicizumab 40. Valsecchi C, Gobbi M, Beeg M, Adams T, Castaman G, Schiavone L, Huntington JA, Peyvandi F. Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor. J Thromb Haemost. 2021; 19: 711-718. 41. Schmitt C, Emrich T, Chebon S, Fernandez E, Petry C, Yoneyama K, Kiialainen A, Howard M, Niggli M, Paz-Priel I, Chang T. Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia. 2021; 27: 984-992. 42. Kaneda M, Kawasaki R, Matsumoto N, Abe H, Tashiro Y, Inokuchi Y, Yasuno H, Sasaki-Noguchi M, Soeda T, Yoshimura Y, Oka T. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A. J Thromb Haemost. 2021; 19: 2938-2946. 5
RkJQdWJsaXNoZXIy MTk4NDMw